Comparing cost of intravenous infusion and subcutaneous biologics in COVID‐19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey

OBJECTIVES: One important group of people at higher risk from the SARS‐CoV‐2(COVID‐19) pandemic are those with autoimmune conditions including rheumatoid arthritis/inflammatory bowel disease. To minimise infection risk, many people have been switched from intravenous to subcutaneous biologics includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Heald, Adrian, Bramham‐Jones, Steven, Davies, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL PAPERS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236906/
https://www.ncbi.nlm.nih.gov/pubmed/33963659
http://dx.doi.org/10.1111/ijcp.14341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236906/
https://www.ncbi.nlm.nih.gov/pubmed/33963659
http://dx.doi.org/10.1111/ijcp.14341

Ejemplares similares